The role of autologous transplantation in Hodgkin lymphoma

Current Hematologic Malignancy Reports

Volumn 6, Issue 3, 2011, Pages 172-179

  Von Tresckow, Bastian ^a   Engert, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

ASCT; Autologous stem cell transplantation; Consolidation; High dose chemotherapy; HL; Hodgkin lymphoma; Maintenance; Salvage; Stem cell transplant; Tandem transplantation

Indexed keywords

BLEOMYCIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CHLOROETHYLNITROSOUREA; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; LOMUSTINE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MITOGUAZONE; NAVELBINE; PANOBINOSTAT; PREDNIMUSTINE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; EVENT FREE SURVIVAL; HEMATOCRIT; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MEDIASTINUM MASS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SALVAGE THERAPY; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HODGKIN DISEASE; HUMANS; RECURRENCE; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS;

EID: 80055064605     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-011-0091-0     Document Type: Article

References (58)

1. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363:640-52.
2. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28:4199-206.
3. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPPABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348:2386-95. (Pubitemid 36682817)
4. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478-84.
5. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27:4548-54.
6. Fleury J, Legros M, Colombat P, et al. High-dose therapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin's disease. Leuk Lymphoma. 1996;20:259-66. (Pubitemid 126714878)
7. Gianni AM, Siena S, Bregni M, et al. Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease. Ann Oncol. 1991;2:645-53.
8. Carella AM, Pollicardo N, Pungolino E, et al. Autologous stem cell transplantation as adjuvant treatment vs no further therapy for poor-risk Hodgkin's disease in first complete remission after MOPP/ABVD. Leuk Lymphoma 15 Suppl 1:59-61, 1995.
9. Arakelyan N, Berthou C, Desablens B, et al. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: fiveyear results of a randomized trial on behalf of the GOELAMS Group. Cancer. 2008;113:3323-30.
10. Federico M, Bellei M, Brice P, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol. 2003;21:2320-5. (Pubitemid 46621870)
11. Carella AM, Bellei M, Brice P, et al. High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results. Haematologica 94:146-8
12. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341:1051-4. (Pubitemid 23114397)
13. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359:2065-71. (Pubitemid 34680969)
14. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2002;20:221-30. (Pubitemid 34032615)
15. Chopra R, McMillan AK, Linch DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood. 1993;81:1137-45. (Pubitemid 23067347)
16. Crump M, Smith AM, Brandwein J, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol. 1993;11:704-11. (Pubitemid 23105679)
17. Gribben JG, Linch DC, Singer CR, et al. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood. 1989;73:340-4. (Pubitemid 19040999)
18. Josting A, Katay I, Rueffer U, et al. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with highdose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM). Ann Oncol. 1998;9:289-95. (Pubitemid 28186799)
19. Rapoport AP, Rowe JM, Kouides PA, et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol. 1993;11:2351-61.
20. Diehl V, Franklin J, Hasenclever D, et al. BEACOPP, a new doseescalated and accelerated regimen, is at least as effective as COPP/ ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 1998;16:3810-21. (Pubitemid 29001534)
21. Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol. 2002;13:1628-35. (Pubitemid 35331462)
22. Colwill R, Crump M, Couture F, et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol. 1995;13:396-402.
23. Sibon D, Ertault M, Al Nawakil C, et al. Combined ifosfamide, etoposide and oxaliplatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/ EBVP: a prospective monocentre study on 34 patients. Br J Haematol 2011 Mar 8 (Epub ahead of print).
24. Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica. 2007;92:35-41. (Pubitemid 46232656)
25. Todd T, Raj S, Camilleri D, et al. Intermediate dose gemcitabinecisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting-a new standard of care in relapsed or refractory Hodgkin lymphoma? Ann Hematol. 2009;88:1107-12.
26. Moskowitz CH, Yahalom J, Zelenetz AD, et al. High-dose chemoradiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol. 2010;148:890-7.
27. Kuruvilla J, Keating A, Crump M: How I treat relapsed and refractory Hodgkin lymphoma. Blood. 2011 Jan 24 (Epub ahead of print).
28. Brandwein JM, Callum J, Sutcliffe SB, et al. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease. Bone Marrow Transplant. 1990;5:99-103. (Pubitemid 20116086)
29. Stewart AK, Brandwein JM, Sutcliffe SB, et al. Mini-beam as salvage chemotherapy for refractory Hodgkin's disease and non- Hodgkin's lymphoma. Leuk Lymphoma. 1991;5:111-5.
30. Magyari F, Simon Z, Miltényi Z, et al. Successful rituximabbendamustine treatment in progression of Hodgkin Lymphoma after autologous hematopoietic stem cell transplant (auto-HSCT). Haematologica. 2010;95:29.
31. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep. 1986;70:163-9. (Pubitemid 16140378)
32. Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol. 2005;16:116-23. (Pubitemid 40124488)
33. Josting A, Müller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 28:5074-80, 2010.
34. Fung HC, Stiff P, Schriber J, et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood Marrow Transplant. 2007;13:594-600. (Pubitemid 46585934)
35. Morschhauser F, Brice P, Ferme C, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 26:5980-7, 2008.
36. Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:455-62. (Pubitemid 351171699)
37. Smith SM, van Besien K, Carreras J, et al. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol BloodMarrow Transplant. 2008;14:904-12. (Pubitemid 351985028)
38. Puig N, Pintilie M, Seshadri T, et al. High-dose chemotherapy and ASCT in elderly patients with Hodgkin's lymphoma. Bone Marrow Transplant. 2011 Jan 17 (Epub ahead of print).
39. Sureda A, Younes A, Ben-Yehuda D, et al. Final analysis: Phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoietic stem cell transplant [abstract]. ASH Annual Meeting Abstracts. 2010;116:419.
40. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812-21.
41. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52-9. (Pubitemid 43053523)
42. Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood. 2008;112:3989-94.
43. Crocchiolo R, Canevari C, Assanelli A, et al. Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. Leuk Lymphoma. 2008;49:727-33. (Pubitemid 351517218)
44. Jabbour E, Hosing C, Ayers G, et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer. 2007;109:2481-9. (Pubitemid 46906468)
45. Moskowitz AJ, Yahalom J, Kewalramani T, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010;116:4934-7.
46. Castagna L, Bramanti S, Balzarotti M, et al. Predictive value of early 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. Br J Haematol. 2009;145:369-72.
47. Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood. 2007;109:486-91. (Pubitemid 46105942)
48. Johnston PB, Inwards DJ, Colgan JP, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85:320-4.
49. Rodriguez J, Rodriguez MA, Fayad L, et al. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood. 1999;93:3632-6. (Pubitemid 29249808)
50. Zinzani PL, Barbieri E, Bendandi M, et al. CEP regimen (CCNU, etoposide, prednimustine) for relapsed/refractory Hodgkin's disease. Tumori. 1994;80:438-42.
51. Pfreundschuh MG, Rueffer U, Lathan B, et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol. 1994;12:580-6. (Pubitemid 24079902)
52. Aparicio J, Segura A, Garcera S, et al. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol. 1999;10:593-5. (Pubitemid 29305439)
53. Baetz T, Belch A, Couban S, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 2003;14:1762-7. (Pubitemid 38029048)
54. Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol. 2007;18:1071-9. (Pubitemid 47053777)
55. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97:616-23. (Pubitemid 32113392)
56. Bonfante V, Viviani S, Santoro A, et al. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. Br J Haematol. 1998;103:533-5. (Pubitemid 28522464)
57. Hagemeister FB, Tannir N, McLaughlin P, et al. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol. 1987;5:556-61. (Pubitemid 17062492)
58. Ferme C, Bastion Y, Lepage E, et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol. 1995;6:543-9.